Go Pro
NASDAQ:EXOZ

eXoZymes Q2 2026 Earnings Report

eXoZymes logo
$6.52 +0.12 (+1.88%)
As of 10:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Upcoming Event
Earnings Conference Call
eXoZymes Q2 2026
00:00 / 00:00
Live Transcript
Follow Audio

eXoZymes EPS Results

Actual EPS
N/A
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

eXoZymes Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

eXoZymes Announcement Details

Quarter
Q2 2026
Time
N/A
Conference Call Date
Thursday, August 20, 2026
Conference Call Time
5:00PM ET

Earnings Documents

eXoZymes Earnings Headlines

Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
See More eXoZymes Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like eXoZymes? Sign up for Earnings360's daily newsletter to receive timely earnings updates on eXoZymes and other key companies, straight to your email.

About eXoZymes

eXoZymes (NASDAQ:EXOZ), Inc. develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide. Headquartered in the United States, the company distributes its products through direct sales and a global network of distributors, positioning itself to support growth in both research and diagnostic markets.

View eXoZymes Profile